Kaerus Bioscience | In The News

top of page

Abstract Black Wave

In The News

Press Releases

October 22, 2024

BK Channel Openers: A New Hope for Fragile X Treatment – Insights from Kaerus Bioscience CEO Robert Ring

Kaerus Bioscience Announces Initiation of Phase 1 Clinical Trial for its Novel BK Channel Modulator KER-0193 being developed for Fragile X Syndrome

Kaerus CEO Robert Ring to Present on Company's BK Modulator Program at the Gordon Research Conference on Fragile X and Autism-related Disorders

Neurolentech signs technology access partnership with Kaerus Bioscience to advance neurodevelopmental disorder research.

November 28, 2022

Kaerus BIO CEO Robert Ring Chairs Panel on Fragile X and Rett Syndromes at the 2022 Rare CNS & Neurodevelopmental Drug Development Summit

Kaerus Bio CEO Robert Ring Presents as WuXi World Fragile X Syndrome Day

Publications

Large-conductance calcium-activated potassium channel haploinsufficiency leads to sensory deficits in the visual system: a case report.

Perche O et al J Med Case Rep. 2022 May 5;16(1):180.

Electroretinography and contrast sensitivity, complementary translational biomarkers of sensory deficits in the visual system of individuals with fragile X syndrome.

Perche O et al. J Neurodev Disord. 2021 Oct 8;13(1):45.

Visual Behavior Impairments as an Aberrant Sensory Processing in the Mouse Model of Fragile X Syndrome.

Felgerolle C et al Front Behav Neurosci. 2019 Oct 2;13:228.

Rescue of fragile X syndrome phenotypes in Fmr1 KO mice by a BKCa channel opener molecule.

Hébert B et al Orphanet J Rare Dis. 2014 Aug 1;9:124.

Association of a functional deficit of the BKCa channel, a synaptic regulator of neuronal excitability, with autism and mental retardation.

Laumonnier F et al . Am J Psychiatry. 2006 Sep;163(9):1622-9.

bottom of page